compound 5b [PMID: 29457898]   Click here for help

GtoPdb Ligand ID: 9835

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Vβ9/Vδ2 T-cells have been shown to be activated by small molecule phosphoantigens (PAgs). The aryloxy triester phosphoramidate prodrug ProPAgen 5b is a potent and specific activator of these cells as a potential immunotherapeutic agent [1]. The molecular mechanism of action is unkown but evidence supports PAgs binding the intracellular B30.2 domain of butyrophilin 3A1.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 15
Topological polar surface area 92.9
Molecular weight 533.24
XLogP 5.9
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CC(=CCOP(=O)(NC(C(=O)OCc1ccccc1)C)Oc1ccccc1)CO[Si](C(C)(C)C)(C)C
Isomeric SMILES C/C(=C\COP(=O)(N[C@H](C(=O)OCc1ccccc1)C)Oc1ccccc1)/CO[Si](C(C)(C)C)(C)C
InChI InChI=1S/C27H40NO6PSi/c1-22(20-33-36(6,7)27(3,4)5)18-19-32-35(30,34-25-16-12-9-13-17-25)28-23(2)26(29)31-21-24-14-10-8-11-15-24/h8-18,23H,19-21H2,1-7H3,(H,28,30)/b22-18+/t23-,35?/m0/s1
Immunopharmacology Comments
Present since birth,1 Vγ9/Vδ2 T-cells represent the dominant subtype of human γδ T-cells in adult peripheral blood. They expand in response to various infections, including tuberculosis, leprosy, typhoid, malaria, and toxoplasmosis, and studies in primate models have suggested a role in immunity to Mycobacterium tuberculosis. Interestingly, they also exhibited an ability to target and lyse a diverse range of cancer cells in vitro. Such properties have made the Vγ9/Vδ2 subset a major focus in the therapeutic exploitation of γδ T-cells.